PTPRG and nasopharyngeal carcinoma: A tumor-suppressive PTPRG-expressing clone and vector-alone (VA), which were previously established in the HONE1 NPC cell line [14] engineered with a tetracycline-regulated inducible (tet-off) system [17], were used for this antibody array study.